Former Verge Medical CEO Chosen to Lead VDyne

Privately held VDyne Inc. has a new leader. The company recently appointed Mike Buck as chairman and CEO.

Buck has more than 30 years of leadership experience in cardiovascular medical technology. Most recently, he was CEO of Verge Medical and previously was founder and CEO of TRUVIC Medical (acquired by Imperative Care). Earlier in his career, he served as president of Cardinal Health’s Medical Products Division and held senior leadership roles at Abbott, including corporate vice president and global commercial leader for Abbott’s Vascular business, as well as leading Abbott’s global Licensing and Acquisitions function.

“Mike brings deep experience in structural heart and a proven ability to build and lead strong teams. As VDyne advances its clinical programs, his leadership will be critical in guiding the company through its next phase,” VDyne board member Dr. Greg Pearl said.

VDyne has conducted clinical studies across 15 countries, with more than 100 successful transcatheter tricuspid valve replacement (TTVR) procedures to date. The company has received U.S. Food and Drug Administration Breakthrough Device designation and is advancing toward CE Mark and initiation of its U.S. pivotal clinical study, positioning VDyne among companies advancing next-generation TTVR therapies.

“VDyne has built a strong clinical foundation, and the opportunity to improve the lives of patients with tricuspid regurgitation is significant. I look forward to working alongside this team as we advance the technology and continue building the clinical evidence behind it,” Buck stated.

Based in Maple Grove, Minn., VDyne is developing a transcatheter tricuspid valve replacement system for treating tricuspid regurgitation. The firm’s TTVR system is currently under clinical investigation and is not approved for commercial sale in the United States or any other jurisdiction.